Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 1 of the 17 sources its claims cite were checked for support.

Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model

Open access
Liu, Qin, Yin, Xiangfan, Languino, Lucia R., Altieri, Dario C. · 2018 · Statistics in Biopharmaceutical Research

Abstract

To test the anticancer effect of combining two drugs targeting different biological pathways, the popular way to show synergistic effect of drug combination is a heat map or surface plot based on the percent excess the Bliss prediction using the average response measures at each combination dose. Such graphs, however, are inefficient in the drug screening process and it does not give a statistical inference on synergistic effect. To make a statistically rigorous and robust conclusion for drug combination effect, we present a two-stage Bliss independence response surface model to estimate an overall interaction index (τ) with 95% confidence interval (CI). By taking into all data points account, the overall τ with 95% CI can be applied to determine if the drug combination effect is synergistic overall. Using some example data, the two-stage model was compared to a couple of classic models following Bliss rule. The data analysis results obtained from our model reflect the pattern shown from other models. The application of overall τ helps investigators to make decision easier and accelerate the preclinical drug screening.

Overview

CoChat Summary

TL;DR

The paper proposes a two-stage Bliss independence dose–response surface model that estimates an overall interaction index (τ) with a 95% confidence interval for two-drug combinations. It applies the method to LN229 glioblastoma viability data for Gamitrinib plus PI3K inhibitors and compares it with per-dose and one-stage approaches.

Key findings

  • The overall τ with 95% CI classifies combination effects as synergistic when τ < 1, independent when τ = 1, and antagonistic when τ > 1; if the upper confidence bound is below 1, the combination is concluded to be significantly synergistic overall.
  • In the example data, Gamitrinib plus BKM120 showed no overall synergy, while Gamitrinib plus BEZ235 showed significant overall synergy. For BEZ235, all series 95% CIs except Gamitrinib at dose 0.222 were below 1; for BKM120, all CIs crossed or sat above 1.
  • The one-stage Whitehead model agreed with the proposed method for Gamitrinib plus BKM120 (non-synergistic), but for Gamitrinib plus BEZ235 it failed to estimate some parameter variances, leaving an incomplete correlation matrix and producing a SAS warning. It also failed to converge for Lee et al. (2007) data and had a similar issue with Chou and Talalay’s Table 2 data.
  • Bootstrap estimates stabilized after 100 resamples; the 95% CI was computed as exp(mean log τ ± 1.96 × SE), with empirical quantiles recommended for non-normal distributions using a larger number such as 1000 bootstrap samples.

Methods

  • Two-stage modeling: first, single-drug dose–response curves were fit with a four-parameter logistic/Hill equation (U = 1 and L = 0 fixed) using nlsLM in R to estimate log(IC50) and Hill slope; second, the overall τ was estimated from a Bliss response surface via a bisection algorithm and nlsLM, with bootstrap resampling from the bivariate normal distribution of first-stage parameters.
  • Data: LN229 glioblastoma cells were plated in 384-well format and treated in a 7×7 matrix with Gamitrinib and PI3K inhibitors (BKM120, BEZ235) using a 1:3 dilution series from 2.00 μM to 0.008 μM for 18 h at 37°C. Viability was measured by fluorescence and normalized to 10 μM doxorubicin (positive control) and 0.2% DMSO (negative control); inhibition was calculated as 1 − viability. Each combination experiment was run twice, and Gamitrinib quadruplets were averaged.
  • Comparisons: the same examples were analyzed with Zhao et al. (2014) per-dose excess-over-Bliss grid plots and with Whitehead et al. (2008) one-stage SAS NLIN modeling.

Limitations

  • The paper states that Bliss and Loewe are models and are unlikely to capture the full complexity of any drug combination; choosing between them depends on current understanding of whether the drugs act through the same pathway.
  • The proposed two-stage method requires each single drug’s dose–response curve to be well fitted by the Hill equation or four-parameter logistic model; if not, alternative first-stage models are needed, which the authors identify as future work.
  • The paper notes that the bootstrap confidence interval assumes approximate normality of log τ, and that empirical quantiles with a larger bootstrap sample are more robust for non-normal distributions. Evident from the text: the evaluation uses only one cell line and two drug combinations, with no simulation study or formal operating-characteristic assessment reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/19466315.2018.1437071

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 4 Not valid · 14 Not checked · 29 Own results and interpretations

20 more claims

Create a free account to see all 47 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 2

  1. Greco W. R., 1990, Cancer Research, 50, 5318
  2. Loewe S., 1953, Arzneimittelforschung, 3, 285

Cited by

See all 208

Metadata

Authors
Liu, Q., Yin, X., Languino, L. R., & Altieri, D. C.
Affiliations
  • The Wistar Institute (US)
  • Thomas Jefferson University (US)
Venue
Statistics in Biopharmaceutical Research
Published
2018-04-03
Volume
10
Issue
2
Pages
112-122
ISSN
1946-6315 (ISSN-L)
OpenAlex
W2788684488
Cited by
208
References
31
Citations by year
2026: 54 · 2025: 37 · 2024: 37 · 2023: 26 · 2022: 26 · 2021: 16 · 2020: 8 · 2019: 3 · 2018: 1
FWCI
5.33
Type
journal article
Language
en
Open access
Locations
  • Statistics in Biopharmaceutical Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • the Office of the Assistant Secretary of Defense for Health Affairs (W81XWH-13-1-0193)
  • National Institutes of Health (Cancer Center Support Grant (CCSG) CA010815,P01 CA140043)
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Social Sciences › Decision Sciences › Management Science and Operations Research › Optimal Experimental Design Methods
Keywords
drug synergy, Bliss independence model, interaction index, confidence interval estimation, anticancer drug combination, two-stage model, drug screening

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-27, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model. https://app.cochat.ai/papers/10.1080/19466315.2018.1437071
The paper
Liu, Q., Yin, X., Languino, L. R., & Altieri, D. C. (2018). Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model. Statistics in Biopharmaceutical Research. https://doi.org/10.1080/19466315.2018.1437071

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.